Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 184

    1.

    Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression.

    Shah N, Dhar D, El Zahraa Mohammed F, Habtesion A, Davies NA, Jover-Cobos M, Macnaughtan J, Sharma V, Olde Damink SW, Mookerjee RP, Jalan R.

    J Hepatol. 2012 May;56(5):1047-53. Epub 2012 Jan 17.

    PMID:
    22266601
    [PubMed - in process]
    2.

    Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review.

    Boonstra K, Beuers U, Ponsioen CY.

    J Hepatol. 2012 May;56(5):1181-8. Epub 2012 Jan 13.

    PMID:
    22245904
    [PubMed - in process]
    3.

    Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study.

    Pereira G, Guevara M, Fagundes C, Solá E, Rodríguez E, Fernández J, Pavesi M, Arroyo V, Ginès P.

    J Hepatol. 2012 May;56(5):1040-6. Epub 2012 Jan 13.

    PMID:
    22245902
    [PubMed - in process]
    4.

    Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population.

    Cucchetti A, Trevisani F, Cescon M, Ercolani G, Farinati F, Poggio PD, Rapaccini G, Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Pinna AD; Italian Liver Cancer (ITA.LI.CA) Group.

    J Hepatol. 2012 May;56(5):1089-96. Epub 2012 Jan 13.

    PMID:
    22245900
    [PubMed - in process]
    5.

    The impact of organ dysfunction in cirrhosis: survival at a cost?

    Shawcross DL, Austin MJ, Abeles RD, McPhail MJ, Yeoman AD, Taylor NJ, Portal AJ, Jamil K, Auzinger G, Sizer E, Bernal W, Wendon JA.

    J Hepatol. 2012 May;56(5):1054-62. Epub 2012 Jan 13.

    PMID:
    22245890
    [PubMed - in process]
    6.

    PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats.

    Rodríguez-Vilarrupla A, Laviña B, García-Calderó H, Russo L, Rosado E, Roglans N, Bosch J, García-Pagán JC.

    J Hepatol. 2012 May;56(5):1033-9. Epub 2012 Jan 13.

    PMID:
    22245887
    [PubMed - in process]
    7.

    Bacterial resistance in cirrhotic patients: an emerging reality.

    Merli M, Lucidi C.

    J Hepatol. 2012 Apr;56(4):756-7. Epub 2012 Jan 8. No abstract available.

    PMID:
    22230869
    [PubMed - in process]
    8.

    Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®.

    de Lédinghen V, Wong VW, Vergniol J, Wong GL, Foucher J, Chu SH, Le Bail B, Choi PC, Chermak F, Yiu KK, Merrouche W, Chan HL.

    J Hepatol. 2012 Apr;56(4):833-9. Epub 2011 Dec 13.

    PMID:
    22173167
    [PubMed - in process]
    9.

    Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH.

    Salmon D, Bani-Sadr F, Loko MA, Stitou H, Gervais A, Durant J, Rosenthal E, Quertainmont Y, Barange K, Vittecoq D, Shoai-Tehrani M, Alvarez M, Winnock M, Trinchet JC, Dabis F, Sogni P.

    J Hepatol. 2012 Apr;56(4):862-8. Epub 2011 Dec 13.

    PMID:
    22173166
    [PubMed - in process]
    10.

    Renal failure and cirrhosis: a systematic review of mortality and prognosis.

    Fede G, D'Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D, Morabito A, Burroughs AK.

    J Hepatol. 2012 Apr;56(4):810-8. Epub 2011 Dec 13.

    PMID:
    22173162
    [PubMed - in process]
    11.

    The CXCL1 rs4074 A allele is associated with enhanced CXCL1 responses to TLR2 ligands and predisposes to cirrhosis in HCV genotype 1-infected Caucasian patients.

    Nischalke HD, Berger C, Luda C, Müller T, Berg T, Coenen M, Krämer B, Körner C, Trebicka J, Grünhage F, Lammert F, Nattermann J, Sauerbruch T, Spengler U.

    J Hepatol. 2012 Apr;56(4):758-64. Epub 2011 Dec 13.

    PMID:
    22173151
    [PubMed - in process]
    12.

    Error occurred: cannot get document summary

    PMID:
    22133567

    13.

    The quest for the elusive factors that underpin neutrophil dysfunction in cirrhosis goes on.

    Manakkat Vijay GK, Taylor NJ, Shawcross DL.

    J Hepatol. 2012 May;56(5):1212-3; author reply 1213-4. Epub 2011 Nov 27. No abstract available.

    PMID:
    22127281
    [PubMed - in process]
    14.

    Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.

    Cárdenas A, Ginès P, Marotta P, Czerwiec F, Oyuang J, Guevara M, Afdhal NH.

    J Hepatol. 2012 Mar;56(3):571-8. Epub 2011 Oct 23.

    PMID:
    22027579
    [PubMed - in process]
    15.

    Towards common denominators in primary biliary cirrhosis: the role of IL-12.

    Lleo A, Gershwin ME, Mantovani A, Invernizzi P.

    J Hepatol. 2012 Mar;56(3):731-3. Epub 2011 Oct 15. No abstract available.

    PMID:
    22005588
    [PubMed - in process]
    16.

    A potential retroviral aetiology for mouse PBC: more answers or more questions?

    Jones DE.

    J Hepatol. 2011 Oct;55(4):750-2. Epub 2011 Mar 9. No abstract available.

    PMID:
    21396414
    [PubMed - indexed for MEDLINE]
    17.

    Mouse mammary tumor virus in anti-mitochondrial antibody producing mouse models.

    Zhang G, Chen M, Graham D, Subsin B, McDougall C, Gilady S, Kneteman M, Law L, Swain M, Trauner M, Wrzesinski S, Flavell R, Wasilenko S, Mason A.

    J Hepatol. 2011 Oct;55(4):876-84. Epub 2011 Feb 18.

    PMID:
    21334408
    [PubMed - indexed for MEDLINE]
    18.

    Serum metabolomics reveals γ-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease.

    Soga T, Sugimoto M, Honma M, Mori M, Igarashi K, Kashikura K, Ikeda S, Hirayama A, Yamamoto T, Yoshida H, Otsuka M, Tsuji S, Yatomi Y, Sakuragawa T, Watanabe H, Nihei K, Saito T, Kawata S, Suzuki H, Tomita M, Suematsu M.

    J Hepatol. 2011 Oct;55(4):896-905. Epub 2011 Feb 18.

    PMID:
    21334394
    [PubMed - indexed for MEDLINE]
    19.

    A variant in myeloperoxidase promoter hastens the emergence of hepatocellular carcinoma in patients with HCV-related cirrhosis.

    Nahon P, Sutton A, Rufat P, Charnaux N, Mansouri A, Moreau R, Ganne-Carrié N, Grando-Lemaire V, N'Kontchou G, Trinchet JC, Pessayre D, Beaugrand M.

    J Hepatol. 2012 Feb;56(2):426-32. Epub 2011 Sep 8.

    PMID:
    21907168
    [PubMed - indexed for MEDLINE]
    20.

    Do fatigue and UDCA therapy truly have independent effects on mortality in PBC?

    Yousuf F, Yeoman AD.

    J Hepatol. 2011 Sep;55(3):729; author reply 729-30. Epub 2011 Feb 11. No abstract available.

    PMID:
    21316409
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk